Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Merck
Baxter
Mallinckrodt
Medtronic

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR GADOXETATE DISODIUM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Gadoxetate Disodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01867424 ↗ Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2013-05-14 Background: - Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used to help identify damaged liver tissue, can help tell these types of prostate cancer apart. It may be able to identify if a man has a type of prostate cancer for which hormone therapy may not work as well. Objectives: - To see if gadoxetate can help identify different types of prostate cancers during imaging studies. Eligibility: - Men at least 18 years of age who have prostate cancer. Participants will be having surgery to either remove the prostate or take tumor tissue samples. Design: - Participants will be screened with a physical exam and medical history. Blood samples will be collected. - Participants will have a magnetic resonance imaging (MRI) scan of the lower torso. They will receive gadoxetate during the MRI scan. - Participants who have surgery will have a sample of their tumor cells collected. Those who have a biopsy will provide cells from this biopsy for study. - Treatment will not be provided as part of this study.
NCT02156739 ↗ Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions Recruiting National Cancer Institute (NCI) N/A 2014-10-13 This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.
NCT02156739 ↗ Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions Recruiting M.D. Anderson Cancer Center N/A 2014-10-13 This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.
NCT02226666 ↗ Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration Completed University of Michigan 2013-08-01 The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
NCT02431598 ↗ Eovist vs. Dotarem Healthy Volunteer MRI Completed University of California, San Diego Phase 4 2015-06-01 The purpose of this study is to evaluate changes in volunteer breath-holding capacity in response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These subjects will be given three, blinded, randomized injections while undergoing an MRI of their liver and holding their breath. During the scan, the subjects' oxygen saturation and heart rate will be closely monitored. Following the scan, the subjects will complete a questionnaire regarding the breath hold.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gadoxetate Disodium

Condition Name

Condition Name for Gadoxetate Disodium
Intervention Trials
Advanced Adult Hepatocellular Carcinoma 1
Liver and Intrahepatic Bile Duct Disorder 1
Primary Malignant Liver Neoplasm 1
BCLC Stage 0 Adult Hepatocellular Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gadoxetate Disodium
Intervention Trials
Liver Neoplasms 4
Carcinoma, Hepatocellular 2
Liver Diseases 2
Bile Duct Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gadoxetate Disodium

Trials by Country

Trials by Country for Gadoxetate Disodium
Location Trials
United States 11
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gadoxetate Disodium
Location Trials
North Carolina 2
Colorado 1
Massachusetts 1
Illinois 1
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gadoxetate Disodium

Clinical Trial Phase

Clinical Trial Phase for Gadoxetate Disodium
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gadoxetate Disodium
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gadoxetate Disodium

Sponsor Name

Sponsor Name for Gadoxetate Disodium
Sponsor Trials
National Cancer Institute (NCI) 4
Nova Scotia Health Authority 1
Slawa Cwajna 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gadoxetate Disodium
Sponsor Trials
Other 14
NIH 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Colorcon
McKesson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.